RCUS Arcus Biosciences, Inc.
Pharmaceutical Preparations · NYSE · SEC CIK 1724521 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-58.3%
TTM net income YoY-32.8%
TTM EPS YoY-6.4%
Revenue 3-yr CAGR-5.9%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-475.0%
Net margin-453.0%
FCF margin-466.0%
EBITDA margin-465.0%
Returns
ROE-114.1%
ROA-50.6%
ROIC (approx.)-124.0%
Asset turnover0.11x
Leverage & solvency
Liabilities / assets56.2%
Debt / equity0.28x
Current ratio3.34x
Interest coverage-43.18x
Cash quality & payout
Operating cash flow / net income1.03x
Accruals ratio1.3%
Payout ratio—
Capex / revenue1.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $247.00M | $258.00M |
| R&D expense | $523.00M | $448.00M |
| SG&A expense | $110.00M | $120.00M |
| Operating income | -$386.00M | -$330.00M |
| Interest expense | $8.00M | $4.00M |
| Pretax income | -$353.00M | -$282.00M |
| Income tax | $0 | $1.00M |
| Net income | -$353.00M | -$283.00M |
| EBITDA | -$376.00M | -$320.00M |
| EPS (basic) | -3.29 | -3.14 |
| EPS (diluted) | -3.29 | -3.14 |
| Weighted avg. shares (diluted) | 107.40M | 90.10M |
| Balance sheet | ||
| Cash & equivalents | $222.00M | $150.00M |
| Short-term investments | $759.00M | $828.00M |
| Current assets | $1.01B | $1.02B |
| PP&E, net | $40.00M | $47.00M |
| Total assets | $1.14B | $1.15B |
| Current liabilities | $231.00M | $226.00M |
| Long-term debt | $99.00M | $48.00M |
| Total debt | $99.00M | $48.00M |
| Total liabilities | $508.00M | $665.00M |
| Shareholders' equity | $631.00M | $485.00M |
| Net debt | -$123.00M | -$102.00M |
| Shares outstanding | 125.30M | 92.20M |
| Cash flow statement | ||
| Operating cash flow | -$482.00M | -$170.00M |
| Capital expenditure | $2.00M | $6.00M |
| Free cash flow | -$484.00M | -$176.00M |
| Investing cash flow | $66.00M | -$84.00M |
| Financing cash flow | $488.00M | $277.00M |
| Depreciation & amortization | $10.00M | $10.00M |
| Stock-based compensation | $60.00M | $76.00M |
Free plan shows the latest 2 periods; Pro shows all 10 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.